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New! 
New! 
Recommendations and Resources for the Control of Influenza  
and Pneumococcal Disease:  2015 – 2016   
 
Everyone aged 6 months and older should receive flu vaccine every year. 
Vaccination should not be delayed to procure a specific vaccine formulation. 
Begin offering flu vaccine as soon as it is available.   
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What’s New for the 2015-2016 Flu Season? 
 
• Choice of influenza vaccine formulation 
This year there is no preferential recommendation for any one age-appropriate approved flu 
formulation over another.  Choice of which influenza vaccine formulation to use should primarily 
be driven by the age indication, contraindications and precautions.  There is no current 
preference for: 
LAIV vs. IIV  quadrivalent vs. trivalent    high-dose vs. standard dose  
 
• Doses needed for children 6 months through 8 years of age 
 Children 6 months through 8 years who have previously received 2 or more total doses of 
trivalent or quadrivalent influenza vaccine as of July 1, 2015 need only 1 dose for the 
2015-16 season.  The 2 previous doses do not need to have been given during the same 
season or consecutive seasons. 
 Children 6 months through 8 years who have previously received only 1 dose or no doses 
of influenza vaccine need two doses of vaccine to be fully protected for the 2015-2016 
season. 
• 2015-2016 influenza vaccine formulations 
For 2015–16, U.S.-licensed influenza vaccines contain new two strains which are different from 
those in the 2014–15 vaccine. 
 Trivalent influenza vaccines contain: 
• an A/California/7/2009 (H1N1)pdm09-like virus 
• an A/Switzerland/9715293/2013 (H3N2)-like virus (New!) 
• a B/Phuket/3073/2013-like (Yamagata lineage) virus (New!) 
 Quadrivalent vaccines contain the above three viruses and a second influenza B strain, 
B/Brisbane/60/2008-like (Victoria lineage) virus.  
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• Most manufacturers began shipping 2015-2016 influenza vaccine in July 2015.  There are 
delays affecting LAIV (FluMist), as well as some other formulations.  However, it is expected 
that there will be adequate supplies of flu vaccine to meet the overall demand this flu season.   
 
For complete guidance, see 2015-2016 Influenza Vaccine Recommendations from the Advisory 
Committee on Immunization Practices (ACIP). 
 
Influenza Vaccination Rates in Massachusetts: 
During the 2013-2014 flu season, 53% of Massachusetts residents received flu vaccine. The highest 
rate (87%) in Massachusetts was among children 6 months - 4 years of age, where we ranked 2nd in 
the nation.  The lowest rate (45%) was among adults 18-64 years of age.  As you can, see no 
significant improvements were achieved. 
 
Your recommendation and offer of vaccine are the most important determinants of 
whether or not your patient gets vaccinated.  
 
According to the 2010-2011 Pregnancy Risk Assessment Monitoring System (PRAMS), 75% 
of pregnant women in Massachusetts whose provider offered them flu vaccine received the 
vaccine, compared with only 35% of pregnant women whose provider did not offer vaccine.  
These data underscore the importance of providers not only strongly recommending 
vaccination, but also offering vaccine on site.   
 
Influenza Vaccine Recommendations: 
The ACIP’s 2015-2016 Influenza Vaccine Recommendations are summarized below. 
 
Timing of Flu Vaccination: 
To avoid missed opportunities for vaccination, providers should offer flu vaccination during routine 
health-care visits and hospitalizations as soon as vaccine is available.  However, as long as flu 
viruses are circulating, vaccination should continue to be offered throughout the flu season, 
even in January or later.  While seasonal influenza outbreaks can happen as early as October, most 
of the time influenza activity peaks in January or later.  Since it takes about two weeks after 
vaccination for antibodies to develop in the body that protect against influenza virus infection, it is 
best that people get vaccinated so they are protected before influenza begins spreading in their 
community.  In New England, flu activity lasts usually through April and May. 
Age Group MA 2012-13 MA 2013-2014 Change in Percentage Points 
between 2012-2013 and 2013-2014 
Everyone 6 mos + 58% 53% -5 
Children 6 mos – 17 yrs 75% 72% -3 
• Children 6 mos – 4 yrs 83% 87% +4 
• Children 5 – 12 yrs 78% 72% -6 
• Adolescents 13 – 17 yrs 67% 61% -6 
Adults 18 yrs + 53% 49% -4 
• Adults 18 – 64 yrs 49% 45% -4 
• Adults, 18-64 yrs, High 
Risk 
58% 58% 0 
• Adults 65 yrs + 71% 64% -7 
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New! 
New! 
Use Flu Season to Assess Patients for the Need for Pneumococcal and Other Vaccines: 
Use annual flu vaccination to assess patients for the need for other vaccines, including Tdap and 
pneumococcal conjugate (PCV13) and pneumococcal polysaccharide (PPSV23) vaccines.  
 
Use IIV or LAIV in Children 2 through 8 Years of Age: 
For 2015-16 flu season, CDC and ACIP recommend annual influenza vaccination for children  
2 through 8 years of age with either nasal spray flu vaccine (i.e., LAIV) or injectable flu vaccine (i.e., 
IIV), with no preference expressed for either vaccine when either one is otherwise appropriate and 
available.   
 
Please note: the 2014-2015 preference for using the nasal spray flu vaccine (LAIV) instead of 
injectable flu vaccine (IIV) for healthy children 2 through 8 years of age was not renewed.  More 
information is available at: http://www.cdc.gov/media/releases/2015/s0226-acip.html and the 2015-
2016 Influenza Vaccine Recommendations.  
 
Vaccine Dose Considerations for Children 6 Months through 8 Years of Age:   
A new algorithm for determining the appropriate number of doses for children aged 6 months 
through 8 years has been developed.  This guidance reflects the thinking that H1N1 pandemic 
vaccine strain is no longer believed to be antigenically novel and that we have 2 other new vaccine 
strains for the A/H3N2 and B/Yamagata vaccine components. 
• Children 6 months through 8 years who have previously received 2 or more total doses of 
trivalent or quadrivalent influenza vaccine as of July 1, 2015 need only 1 dose for the 2015-
16 season.  The two previous doses do not need to have been given during the same season 
or consecutive seasons.   
• Children 6 months through 8 years who have previously received only 1 dose or no doses of 
influenza vaccine need two doses of vaccine to be fully protected for the 2015-2016 season.  
 
Figure 1: Flu vaccine dosing algorithm for children 6 months through 8 years of age, 
2015-2016 
 
1 The 2 doses need not have been received during the same season or consecutive seasons. 
2 Doses should be administered > 4 weeks apart.   
 
Note:  Children 6 months through 8 years of age who have not received 2 or more 
doses in any previous season as described above require 2 doses in 2015-16. 
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Information for Travelers:   
The Southern Hemisphere experiences its flu season from April through September, and flu activity 
can occur year-round in the tropics.  People traveling to parts of the world where flu activity is 
ongoing, and who have not received flu vaccine for the current season, should get vaccinated.  This 
is particularly important for people at risk for flu-related complications.  This also applies to people 
who are traveling in the temperate regions of the Northern Hemisphere as part of tourist groups 
(e.g., on cruise ships) that may include people from other parts of the world where flu activity is 
ongoing.  For more information, go to: www.cdc.gov/flu/travelers/travelersfacts.htm  
 
Influenza, Neurologic and Neuromuscular Conditions, and Congregate Housing: 
Children and adults with neurological and neuromuscular conditions (including disorders of the brain, 
spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy [seizure disorders], 
stroke, intellectual disability [mental retardation], moderate to severe developmental delay, muscular 
dystrophy, or spinal cord injury) are at increased risk of complications from influenza.  These 
conditions can compromise respiratory function, handling of secretions and increase the risk of 
aspiration.  Like everyone else six months of age and older, they should receive influenza vaccine 
every year.  A CDC study found that in 2011-2012, only about half of children and young adults 
within this high risk group received influenza vaccine.   
 
People with neurological and neuromuscular conditions who live in congregate housing (e.g., group 
homes) and/or attend day programs may be exposed to influenza throughout the season.  They 
should receive flu vaccine as soon as it is available.  Staff at these facilities should be vaccinated as 
well.  In addition, when outbreaks of influenza-like illness (fever with cough and/or sore throat) occur 
in a group home or day program serving vulnerable populations, healthcare providers should be 
immediately notified and should consider rapid antiviral treatment of ill individuals as well as antiviral 
prophylaxis of individuals who were exposed.   
 
Outbreaks across the age spectrum in these settings have occurred annually in Massachusetts and 
have resulted in serious illness and even death.  So, MDPH recommends: 
 Annual vaccination of residents and staff, and rapid outbreak response can prevent serious 
illness and death. 
 During flu season it can be challenging to coordinate a response in a timely manner.  
Therefore, proactive development of an influenza outbreak response protocol within agencies 
serving vulnerable populations, facilitates a rapid response when an outbreak occurs.  For 
more information see 
http://www.cdc.gov/ncbddd/developmentaldisabilities/features/keyfinding-flu-vaccine-
neurologic.html 
 Notification of MDPH and other appropriate agencies immediately is essential (see pages 7 
and 8). 
 
 
See the table on next page for the Approved Influenza Vaccines for Different Ages 2015-2016. 
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Table 4. Approved Influenza Vaccines for Different Ages 2015-20161 
Vaccine Trade Name Manufacturer Presentation Mercury 
Content from 
Thimerosal 
(µg Hg/0.5 mL) 
Ovalbumin 
Content  
(µg/0.5 mL) 
Age 
Indication 
Route 
Inactivated 
Quadrivalent 
(IIV4) 
 
Standard 
Dose 
Fluarix 
Quadrivalent 
GSK 
0.5 mL PFS 0.0 < 0.05 > 3 yrs IM 
FluLaval 
Quadrivalent 
ID Biomedical 
(distributed by 
GSK) 
5.0 mL MDV < 25.0 < 0.3 > 3 yrs IM 
Fluzone 
Quadrivalent 
Sanofi Pasteur 0.25 mL PFS 0.0 0.01-0.02 mcg/ 0.25 mL2 6 - 35 mos IM 
0.5 mL PFS 0.0 
0.02-0.042 
> 36 mos IM 
0.5 mL  SDV 0.0 > 36 mos IM 
5.0 mL MDV 25 >6 mos IM 
Fluzone 
Intradermal3 
Sanofi Pasteur 0.1 mL 
prefilled 
microinjection 
0.0 0.02mcg/ 0.1 mL2 18-64 yrs ID 
 
Inactivated 
Influenza 
Vaccine, 
Trivalent 
(IIV3) 
Standard 
Dose 
Afluria bioCSL  
0.5 mL PFS 0.0 
< 1 
> 9 yrs via 
needle4 
IM 
5.0 mL MDV 24.5 
> 9 yrs via 
needle4;  
18-64 yrs via 
jet injector4 
Fluvirin Novartis 0.5 mL PFS 
(Tip cap may contain 
natural rubber latex) 
< 1 
< 1 >4 yrs 
IM 
5.0 mL MDV 25.0 IM 
Fluzone Sanofi Pasteur 
5.0 mL MDV 25.0 0.12 > 6 mos IM 
IIV3 Cell 
Culture Based 
(ccIIV3) 
Standard Dose 
Flucelvax Novartis 0.5 mL PFS 
(Tip cap may contain 
natural rubber latex) 
0.0 See Footnote 5 > 18 yrs IM 
IIV3 
High Dose6 
Fluzone High 
Dose 
Sanofi Pasteur 
0.5 mL PFS 0.0 0.12 > 65 yrs IM 
Recombinant 
Trivalent   
(RIV3) 
Flublok Protein 
Sciences 0.5 mL SDV 0.0 0.0 >18 yrs IM 
Live 
attenuated 
influenza 
virus (LAIV) 
FluMist 
Quadrivalent  
Medimmune .2 mL single 
dose prefilled 
intranasal 
sprayer 
0.0 
<0.24 (per 
0.2mL) 
2 – 49 years, 
healthy, non-
pregnant 
IN 
Abbreviations:  IM= intramuscular, ID=intradermal, IN=intranasal; MDV= multi-dose vial, PFS= (single-dose) prefilled 
syringe, SDV= single-dose vial 
(See next page for footnotes.) 
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1 Check Food and Drug Administration for approved prescribing information for 2015-16 influenza vaccines for 
the most updated information, including (but not limited to) indications, contraindications, and precautions. 
Package inserts are available at 
www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm 
2  Personal communication Sanofi Pasteur.  Concentration of ovalbumin in 0.25 mL PFS presentation of 
Fluzone Quadrivalent is extrapolated from the concentration in 0.5 mL presentation. 
3 Quadrivalent inactivated vaccine, intradermal:  A 0.1-mL dose contains 9 μg of each vaccine antigen (36 μg 
total). 
4 Age indication per package insert is ≥ 5 years; however, the ACIP recommends Afluria not be used in children 
aged 6 months through 8 years because of increased risk of febrile reactions noted in this age group with 
bioCSL’s 2010 Southern Hemisphere IIV3 formulation.  If no other age-appropriate, licensed inactivated 
seasonal influenza vaccine is available for a child aged 5 - 8 years who has a medical condition that increases 
the child's risk for influenza complications, Afluria can be used.  Discuss with the parents or caregivers the 
benefits and risks of influenza vaccination with Afluria before administering this vaccine.  Afluria may be used in 
persons >9 years. 
5 For Flucelvax this information is not included in package insert.  The total egg protein is estimated to be less 
than 50 femtograms (5x10-8µg) total egg protein (and less ovalbumin) per 0.5 mL dose of Flucelvax. 
6 Trivalent inactivated vaccine, high-dose: A 0.5-mL dose contains 60 μg of each vaccine antigen (180 μg total). 
 
Evaluation and Management of Those with a History of Egg Allergies:  
• Persons with a history of egg allergy who experience only hives after exposure to egg should 
receive influenza vaccine.  Because relatively fewer data are available for use of LAIV in this 
situation, use IIV or RIV.  RIV is egg-free and may be used for persons aged >18 years who have 
no other contraindications.  However, IIV (egg- or cell-culture based) may also be used, with the 
following additional safety measures:  
• Vaccine should be administered by a healthcare provider who is familiar with the potential 
manifestations of egg allergy; and 
• Observe vaccine recipients for at least 30 minutes for a reaction after administration of each 
dose. 
• Persons who have had reactions to egg involving such symptoms as angioedema, respiratory 
distress, lightheadedness, or recurrent emesis; or who required epinephrine or another emergency 
medical intervention may receive RIV3, if aged >18 years and there are no other contraindications.  
If RIV3 is not available or recipient is not within the indicated age range, IIV should be 
administered by a physician with experience in the recognition and management of severe allergic 
conditions. 
• Some persons who report allergy to egg might not be egg-allergic.  Those who are able to eat 
lightly cooked egg (e.g., scrambled egg) without reaction are unlikely to be allergic.  Egg-allergic 
persons might tolerate egg in baked products (e.g., bread or cake).  Tolerance to egg-containing 
foods does not exclude the possibility of egg allergy.  Confirm egg allergy with a consistent medical 
history of adverse reactions to eggs and egg-containing foods, plus skin and/or blood testing for 
immunoglobulin E antibodies to egg proteins. 
• For individuals who have no known history of exposure to egg, but who are suspected of being 
egg-allergic on the basis of previously performed allergy testing, consultation with a physician with 
expertise in the management of allergic conditions should be obtained prior to vaccination.  
Alternatively, RIV3 may be administered if the recipient is aged >18 years. 
• CDC is continuing to monitor the data available about the safety of giving IIV and LAIV to those 
with egg allergy. 
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The algorithm below summarizes these recommendations for management of persons who 
report an allergy to eggs. 
 
Influenza Surveillance:  
Throughout the year, and especially during flu season, conduct surveillance for respiratory illness 
with fever and use influenza testing to identify outbreaks so infection control measures can be 
promptly initiated in all settings, including inpatient and outpatient settings.   
Influenza Reporting:   
All positive laboratory findings indicative of influenza virus infection are reportable directly to MDPH, 
in accordance with 105 CMR 300.000 (Reportable Diseases, Surveillance and Isolation and 
Quarantine Requirements).  
1) Immediately report the following influenza-related cases by phone to the Division of 
Epidemiology and Immunization at 617-983-6800 and to your local board of health.  Providers 
in the city of Boston should report these cases directly to the Boston Public Health Commission at 
617-534- 5611.  This applies to all strains of influenza: 
 Suspected and confirmed deaths related to influenza in children under 18 and in pregnant women 
 Unusual or unusually severe cases of influenza or ILI (e.g., with encephalopathy, myocarditis, or 
 pericarditis) 
 Case(s) or clusters of ILI in long-term care facilities, group homes, shelters, prisons or other high risk 
 settings 
 Unusual clusters of ILI in daycare and elementary schools 
 Cases of suspected or proven antiviral treatment or prophylaxis failure 
 Suspect novel or variant influenza, e.g., travel-associated, animal-associated, avian influenza A H5N1 
or H7N9, influenza A H3N2v, other highly pathologic avian influenza  
 ILI in employees of swine or poultry farms 
No 
Can the person eat lightly cooked 
egg (e.g., scrambled egg) without 
reaction?  
After eating eggs or egg-containing 
foods, does the person experience 
ONLY hives? 
 
Administer RIV3, if pt >18 years 
OR 
Administer IIV and observe for 
reaction for at least 30 minutes 
after vaccination 
No 
After eating eggs or egg-containing products, does 
the person experience other symptoms such as 
• Cardiovascular changes (e.g., hypotension)? 
• Respiratory distress (e.g., wheezing)? 
• Gastrointestinal (e.g., nausea/ vomiting)? 
• Reaction requiring epinephrine? 
• Reaction requiring emergency medical attention? 
 
Yes 
Yes 
Administer vaccine per usual 
protocol 
 
Yes 
Administer RIV3, if pt >18 years 
OR 
If RIV3 is not available, is 
contraindicated, or patient is <18 
years, IIV should be administered 
by a physician with experience in 
the recognition and management 
of severe allergic conditions. 
Observe for reaction for at least 30 
minutes after vaccination 
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Clusters in hospitals and long-term care:  Report clusters of influenza-like illness to MDPH via 
faxed teleform.  Teleforms are available by calling 617-983-6801.  Please provide as much detail 
on these forms as possible.  Upon receipt of the teleform, an epidemiologist will contact you to 
provide guidance concerning testing, prophylaxis and infection control.  Clusters in hospitals, long 
term care facilities and other entities licensed by the Division of Healthcare Quality (DHCQ) should 
also be reported to DHCQ at 800-462-5540 or 617-753-8150.  Group homes, prisons or other 
settings should also contact the appropriate oversight agency for your facility. 
2) Report rapid influenza flu test results by teleform:  A teleform for reporting positive results of 
rapid influenza tests to MDPH is available by calling 617-983-6801. 
3) More about reporting:  For specific information about reporting, see the MDPH 105 CMR 
300.000:  Reportable Diseases, Surveillance and Isolation and Quarantine Requirements at 
www.mass.gov/eohhs/docs/dph/cdc/reporting/rdiq-reg-summary.rtf.  Please note that additional 
jurisdiction-specific reporting requirements may also apply.  For example, healthcare providers and 
laboratories within the city of Boston must also report all cases of influenza and all laboratory tests 
positive for influenza directly to the Boston Public Health Commission (see www.bphc.org/ or contact 
BPHC at 617-534-5611). 
 
 
Influenza testing and infection control (including antiviral treatment), below:  Providers 
should routinely check for updates at www.mass.gov/flu and www.cdc.gov/flu/professionals/. 
 
 
Influenza Testing:   
Diagnostic testing for influenza can aid clinical judgment and guide treatment decisions and control 
measures.  Clinical testing services performed on specimens submitted to a state public health 
laboratory provide important diagnostic information to the clinician and also contribute to public 
health respiratory surveillance response and control measures.  As a specific example, an influenza 
B strain submitted to the Massachusetts State Public Health Laboratory (MA SPHL) in March 2012 
was the first identified isolate that later began to circulate widely and was then incorporated into the 
2013-14 and 2014-15 influenza vaccines.  Specific testing services provided by the MA SPHL may 
assist the clinician as follows: 
 Define the start of the influenza season:  Rapid antigen testing for detecting influenza A and B 
virus infections is widely available.  Rapid influenza diagnostic tests vary in performance 
characteristics.  False negative and false positive results can occur when flu prevalence is low in 
the community.  For this reason, MA SPHL requests that clinical laboratories consider submitting 
their first influenza rapid positive original samples of the season (beginning in October) to MA 
SPHL for confirmation.  For more information: 
www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm.   
 Diagnose influenza or other respiratory infections:  Diagnostic tests for influenza performed 
at the MA SPHL include a “respiratory panel” to identify seasonal and novel influenza 
types/subtypes followed by testing of influenza negative samples for the presence of adenovirus, 
respiratory syncytial virus (A/B), parainfluenza virus (1-4), coronavirus (HKU1, OC43, NL63, 
229E), human metapneumovirus and rhinovirus/enterovirus using polymerase chain reaction 
(PCR).  There is no charge for these tests.  The turnaround time for results is usually a few days, 
but varies depending on the test performed.  Results are returned electronically or by fax and 
mail to the submitting provider.   
 Monitor trends in influenza antiviral resistance:  MA SPHL performs surveillance testing for 
influenza antiviral resistance and provides this information in its weekly influenza report.  
Diagnostic antiviral resistance testing is currently coordinated with CDC and is offered on a case-
by-case basis.  Providers are encouraged to submit samples from influenza cases with suspect 
antiviral drug resistance.    
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 Rapid identification of new or novel influenza or other viral infections:  MA SPHL is able to 
rapidly determine the presence of a novel or variant influenza strain using the CDC diagnostic 
panel.  Rapid antigen testing and commercially-available RT-PCR tests may not detect novel or 
variant strains of influenza and most are unable to differentiate between seasonal, novel or 
variant influenza strains.  Therefore, respiratory specimens should be collected from any patient 
suspected of having atypical or novel infections with H3N2v or avian influenza H7N9, for 
example.  These suspicions may be based on travel history or animal exposure.  
Specimen Collection and Shipping to MA SPHL: 
Flu specimens should be collected as soon as possible after onset of illness, preferably within three 
days (72 hours).  Specimens collected after 72 hours are usually unsuitable for testing.  Specimens 
should be submitted immediately after collection to MA SPHL in order to be tested within three days 
of collection.  If samples will be shipped to MA SPHL >3 days from collection or on a Friday but are 
collected within 72 hrs, they should be frozen at <-20ºC and shipped with ice packs on Monday.  This 
variation must be noted on the specimen submission form to avoid an “unsatisfactory for testing” 
designation.  
 For information on influenza specimen collection and transportation, or to speak with an 
immunization epidemiologist, call MDPH at 617-983-6800.   
 Information of specimen collection and submission, including the A respiratory surveillance 
specimen submission form may be found at: www.mass.gov/eohhs/docs/dph/laboratory-
sciences/flu-virus-collection.pdf and www.mass.gov/eohhs/docs/dph/laboratory-sciences/flu-
specimen-submission-form.pdf. 
 
Infection Control:  To prevent the transmission of all respiratory infections, including influenza, in 
health care settings, implement the following infection control measures at the first point of contact 
with a potentially infected person.  These should be incorporated into infection control practices as 
one component of standard precautions.  Tools to help promote and implement these 
recommendations are available at www.cdc.gov/flu/professionals/infectioncontrol.  
1) Assess the influenza and pneumococcal vaccination status of all patients and the flu 
vaccination status of all staff.  Vaccinate all susceptible patients and staff. 
2) Use standard precautions (www.cdc.gov/hicpac/2007IP/2007ip_part3.html#a) with all patients.  
Use droplet precautions (www.cdc.gov/hicpac/2007IP/2007ip_part3.html#b) when caring for patients 
with suspected or confirmed seasonal influenza.   
3) Active surveillance and testing for new illness and cases:  Educate staff about the signs and 
symptoms of influenza-like illness. 
4) Respiratory hygiene/cough etiquette:  Post visual alerts (in appropriate languages) at the 
entrance to outpatient facilities (e.g., emergency departments, physician offices, outpatient clinics) 
instructing patients and persons who accompany them (e.g., family, friends) to inform health care 
personnel of symptoms of a respiratory infection when they first register for care and to practice 
respiratory hygiene/cough etiquette.  Posters, brochures and fact sheets promoting cough etiquette 
and handwashing in multiple languages are available from the Massachusetts Health Promotion 
Clearinghouse at https://massclearinghouse.ehs.state.ma.us/ .  
5) Novel strains of influenza:  If you suspect any novel strain of influenza, please contact your local 
board of health and MDPH immediately at 617-983-6800.  Highly-pathogenic avian influenza (HPAI) 
A H5 viruses have been identified in birds in the United States since December 2014.  The majority 
of these infections have occurred in poultry, including backyard and commercial flocks.  There have 
been no cases identified in Massachusetts birds to date; these HPAI A H5 viruses are not known to 
have caused disease in humans.  Providers should check for updates at  
http://www.cdc.gov/flu/avianflu/index.htm, http://www.cdc.gonbnnv/flu/avianflu/h7n9-virus.htm and at 
http://www.cdc.gov/flu/swineflu/prevention-strategies.htm.  
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6) Antiviral drugs are an adjunct to, not a substitute for, vaccination for preventing and controlling 
influenza.  The neuraminidase inhibitors oseltamivir (Tamiflu®), zanamivir (Relenza®), and peramivir 
(Rapivab®) are currently recommended for use against circulating influenza viruses.  The 
adamantanes (amantadine and rimantadine) are not recommended because of high levels of 
resistance to these drugs among recently circulating influenza A (H3) and 2009 H1N1 influenza 
viruses. 
Prompt empiric antiviral treatment:  Clinical judgment is an important factor in treatment 
decisions for patients presenting with influenza-like illness.  Prompt empiric antiviral treatment 
with influenza antiviral medications is recommended while results of definitive diagnostic tests 
are pending, or if diagnostic testing is not possible, for patients with clinically suspected influenza 
illness who have:  
• Illness requiring hospitalization, 
• Progressive, severe, or complicated illness, regardless of previous health status, and/or   
• Increased risk for severe disease. 
Antiviral treatment, when clinically indicated, should not be delayed pending definitive laboratory 
confirmation of influenza.  Influenza antiviral medications are most effective when initiated within 
the first 2 days of illness, but these medications may also provide benefits for severely ill patients 
when initiated even after 2 days.  Guidance on use of antivirals may change depending upon 
resistance data.  Consult CDC’s latest recommendations on antiviral use at 
www.cdc.gov/flu/professionals/antivirals/. 
Clinicians should be alert to changes in antiviral recommendations that might occur as 
additional antiviral resistance data becomes available during the 2015-2016 season. 
7) Rapid testing reminder:  Point of care rapid tests capable of detecting influenza A and B virus 
infections are available, but health care providers and public health personnel should be aware 
that rapid influenza diagnostic tests have limited sensitivity and false negative results are 
common.  Thus, negative results from rapid influenza diagnostic test should not be used to guide 
decisions regarding treating patients with influenza antiviral medications.  In addition, false positive 
tests can occur and are more likely when influenza is rare in the community.  When laboratory 
confirmation is desired, use RT-PCR and/or viral culture.     
Additional information on the prevention and control of influenza can be found in the influenza 
chapter of the MDPH Guide to Surveillance, Reporting and Control, at 
www.mass.gov/eohhs/docs/dph/disease-reporting/guide/influenza.rtf.  
 
Vaccine Ordering and Locating Clinics: 
Some resources for providers and patients can be found below. 
Providers Wishing to Order Flu Vaccine for Private Purchase: 
The national Influenza Vaccine Availability Tracking System (IVATS) assists providers 
wishing to privately purchase flu vaccine.  IVATS identifies available doses of influenza 
vaccine by formulation and distributor/vendor throughout the season.  
 
Location of Flu and Adult Vaccination Services: 
Flu vaccination clinics are listed on the mylocalclinic.com website sponsored by the 
Massachusetts Health Officers Association (MHOA).  MDPH urges agencies to post their 
clinics on this website.  Many boards of health (BOHs) may have clinics that make flu and 
other vaccines available to both adults and children.  BOHs can be contacted individually for 
questions about possible flu vaccination clinics in Massachusetts municipalities, including the 
age groups served. 
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HealthMap Vaccine Finder assists the public with locating influenza and adult vaccination 
services within their communities.  It is a free, online service where users can search for 
locations that offer immunizations.  Its staff works with partners such as clinics, pharmacies, 
and health departments to provide accurate and up-to-date information about vaccination 
services.  MDPH urges providers and other agencies to register their locations on the 
HealthMap Vaccine Finder site too. 
 
For questions about influenza please call the Massachusetts Department of Public Health 
Immunization Program at 617-983-6800 or your local board of health.   
For questions about state-supplied influenza vaccine, please call the Vaccine Unit at 617-983-6828.  
Pneumococcal Vaccine Recommendations: New! 
 
 
 
Background:  Beginning last season, PCV13 and PPSV23 are recommended to be administered 
routinely in a series to all healthy adults aged ≥65 years.  This year, the optimal interval between 
doses PCV13 and PPSV23 for immunocompetent adults in this age group was updated to be 
>1year (changed from 6-12 months).  This change in recommendation was based on the 
considerations summarized below. 
1) Shorter intervals (e.g. 8 weeks) may be associated with increased reactogenicity. 
2) Longer intervals (>1 year) may lead to an improved immune response.  
3) Changing interval for the PCV13-PPSV23 sequence to ≥1 year simplifies and harmonizes 
the recommendation.  It allows the intervals to be the same, regardless of the order in 
which the two vaccines are given, in immunocompetent adults aged ≥65 years. 
4) The recently revised CMS regulations for pneumococcal vaccines allow for Medicare 
coverage of a different, second pneumococcal vaccine one year after the first vaccine was 
given.  The change in the ACIP recommended interval for the PCV13-PPSV23 sequence 
would make ACIP recommendations consistent with the current Medicare policy.  
Current Recommendations: 
The latest ACIP recommended intervals between PCV13 and PPSV23 vaccines have been 
published in the MMWR. 
 
PCV13 and PPSV23 are recommended to be administered routinely in a series to all 
immunocompetent adults aged ≥65 years. PCV13 should be administered only once for all adults.  
Specific recommendations are based on a person’s previous pneumococcal vaccine history.  
• Persons who are pneumococcal vaccine-naïve. Adults aged ≥65 years who have not 
previously received pneumococcal vaccine or whose previous vaccination history is unknown 
should receive a single dose of PCV13 first, followed by a dose of PPSV23.  The dose of 
PPSV23 should be given >1 year after a dose of PCV13. If PPSV23 cannot be given during this 
time window, the dose of PPSV23 should be given during the next visit.   
• Persons previously vaccinated with PPSV23. Adults aged ≥65 years who have previously 
received ≥1 doses of PPSV23 also should receive a single dose of PCV13 if they have not yet 
received it.  A dose of PCV13 should be given ≥1 year after receipt of the most recent PPSV23 
dose.  For those for whom an additional dose of PPSV23 is indicated, this subsequent PPSV23 
dose should be given >1 year after PCV13 and >5 years after the most recent dose of PPSV23. 
• The two vaccines should not be co-administered.  If doses of PPSV23 and PCV13 are 
inadvertently given on the same day or earlier than the recommended interval, those doses do 
not need to be repeated.  
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• Adults 19 years and older at increased risk for pneumococcal disease who received a dose of 
PCV13 at 64 years or younger should not receive another dose of PCV13 at 65 years or older. 
• For adults >65 years with immunocompromising conditions, functional or anatomic asplenia, CSF 
fluid leaks or cochlear implants, the recommended interval between a dose of PCV13 and 
PPSV23 remains at >8 weeks.  This interval minimized the risk window for invasive 
pneumococcal disease caused by serotypes unique to PPSV23 in these highly vulnerable 
groups. 
 
For more details about the sequential schedule and intervals, please see the algorithm below. 
 
Sequential Administration and Recommended Intervals for PCV13 and PPSV23 
for Immunnocompetent Adults Aged >65 Years 
 
 
PCV13 at age ≥65 years PPSV23 
 
PCV13 
 
≥1 year 
>1 year1,2 
≥1 year 
 
>1 year 
PPSV23 already received at age 
≥65 years 
PPSV23 
 
PPSV23 already 
received at age <65 
years 
PCV13 at age ≥65 
years 
 
Pneumococcal vaccine-naïve persons aged ≥65 years: 
Persons who previously received PPSV23 at age ≥65 years: 
Persons who previously received PPSV23 before age 65 years who are now aged  ≥65 years 
≥5 years3 
1 If doses of PPSV23 and PCV13 are inadvertently given on the same say or earlier than the recommended 
interval, those doses do not need to be repeated. 
2 For adults in this age group with immunocompromising conditions, functional or anatomic asplenia, CSF 
fluid leaks or cochlear implants, the recommended interval is >8 weeks. 
3 For those who previously receivedPPSV23 when aged <65 years and for whom an additional dose of 
PPSV23 is indicated when aged >65 years, this subsequent PPSV23 dose should be given >1 year after 
PCV13 and >5 years after the most recent dose of PPSV23.  
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The recommendations for routine PCV13 use among adults aged ≥65 years will be reevaluated in 
2018 and revised as needed.  CDC’s Pneumococcal Frequently Asked Questions was developed to 
help healthcare professionals address common questions patients ask regarding pneumococcal 
vaccination.  Also, information can be found on CDC’s Pneumococcal Disease and Pneumococcal 
Vaccination web pages.  MDPH’s Control of Influenza and Pneumococcal Disease in Long-Term 
Care Facilities contains additional guidance and will be posted at www.mass.gov/flu. 
 
Insurance Coverage and Pneumococcal Vaccines 
Most private health insurance covers pneumococcal vaccines.  Check with the insurance provider for 
details on whether there is any cost to your patient and for a list of in-network vaccine providers.  
Medicare Part B covers the cost of two recommended doses of pneumococcal vaccine when 
administered 1 year apart. (i.e., 11 full months have passed following the month in which the 
previous pneumococcal vaccine was administered). 
 
As with other preventive care and vaccines, Medicare beneficiaries may not need to pay for the 
immunization if the doctor or other qualified health care provider accepts assignment (Medicare 
payment) for giving the vaccine.  However, patients should check with their provider and plan to 
review the details of their coverage.  Guidance for providers about Medicare Part B billing for 
pneumococcal vaccines can be found at: http://www.cms.gov/Outreach-and-Education/Medicare-
Learning-Network-MLN/MLNMattersArticles/Downloads/MM9051.pdf 
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Vaccine Information Statements (VISs) for all vaccines in many languages: www.immunize.org/vis. 
Standing orders for LAIV, IIV, pneumococcal vaccine, Tdap and other vaccines are available at 
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